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ABSTRACT
Background
Betaine (trimethylglycine) lowers plasma homocysteine, a possible risk factor for
cardiovascular disease. However, studies in renal patients and in obese individuals who are
on a weight-loss diet suggest that betaine supplementation raises blood cholesterol; data in
healthy individuals are lacking. Such an effect on cholesterol would counteract any favourable
effect on homocysteine. We therefore investigated the effect of betaine, of its precursor choline
in the form of phosphatidylcholine, and of the classical homocysteine-lowering vitamin folic
acid on blood lipid concentrations in healthy humans.
Methods and Findings
We measured blood lipids in four placebo-controlled, randomised intervention studies that
examined the effect of betaine (three studies, n = 151), folic acid (two studies, n = 75), and
phosphatidylcholine (one study, n = 26) on plasma homocysteine concentrations. We
combined blood lipid data from the individual studies and calculated a weighted mean
change in blood lipid concentrations relative to placebo. Betaine supplementation (6 g/d) for 6
wk increased blood LDL cholesterol concentrations by 0.36 mmol/l (95% confidence interval:
0.25–0.46), and triacylglycerol concentrations by 0.14 mmol/l (0.04–0.23) relative to placebo.
The ratio of total to HDL cholesterol increased by 0.23 (0.14–0.32). Concentrations of HDL
cholesterol were not affected. Doses of betaine lower than 6 g/d also raised LDL cholesterol,
but these changes were not statistically significant. Further, the effect of betaine on LDL
cholesterol was already evident after 2 wk of intervention. Phosphatidylcholine supplementa-
tion (providing approximately 2.6 g/d of choline) for 2 wk increased triacylglycerol
concentrations by 0.14 mmol/l (0.06–0.21), but did not affect cholesterol concentrations. Folic
acid supplementation (0.8 mg/d) had no effect on lipid concentrations.
Conclusions
Betaine supplementation increased blood LDL cholesterol and triacylglycerol concentrations
in healthy humans, which agrees with the limited previous data. The adverse effects on blood
lipids may undo the potential benefits for cardiovascular health of betaine supplementation
through homocysteine lowering. In our study phosphatidylcholine supplementation slightly
increased triacylglycerol concentrations in healthy humans. Previous studies of phosphati-
dylcholine and blood lipids showed no clear effect. Thus the effect of phosphatidylcholine
supplementation on blood lipids remains inconclusive, but is probably not large.
Folic acid supplementation does not seem to affect blood lipids and therefore remains the
preferred treatment for lowering of blood homocysteine concentrations.
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Cardiovascular disease (CVD) is a major cause of morbidity
and mortality in Western societies. Diet may play a crucial
role in the aetiology of CVD. However, clinical trials that test
the effects of diet on CVD are complicated to conduct.
Hence, risk factors that are predictive of CVD risk are
frequently used to test the effects of diet on disease
prevention. Examples of such risk factors are homocysteine
concentrations and cholesterol concentrations. A limitation
of studying effects of dietary changes on risk factors is that
often a single factor is measured, whereas multiple factors
might be affected by changes in diet. Whether homocysteine
lowering indeed lowers risk of CVD is not yet established, but
evidence for a causal relationship is accumulating [1–3]. The
effects of increased blood low-density lipoprotein (LDL)
cholesterol concentrations on CVD risk are well established.
Betaine is used as therapy to lower plasma homocysteine in
hyperhomocysteinemic patients with genetic defects in their
homocysteine metabolism who are unresponsive to pyridox-
ine, folic acid, and vitamin B12 [4–6]. It also lowers plasma
homocysteine in healthy humans with homocysteine concen-
trations in the normal range [7–9]. Betaine occurs naturally in
the diet, or it can be produced endogenously through
oxidation of choline. Dietary intake of betaine is estimated
at 0.5–2 g/d generally, and major food sources are wheat
products (e.g., bread), beets, and spinach [10]. Recently we
showed that supplementation with 1.5 g/d of betaine, which is
in the range of daily intake, lowers fasting and post-
methionine plasma homocysteine concentrations in healthy
humans [8]. The homocysteine-lowering properties of betaine
would predict a decrease in risk of CVD. However, betaine
and its precursor choline are also involved in lipid metabo-
lism. In animal studies betaine supplementation increases
serum cholesterol concentrations relative to control [11,12].
Studies in humans have also found that betaine supplemen-
tation increases serum cholesterol in obese individuals who
are on a weight-loss diet, and in patients with chronic renal
failure [9,13]. However, in these studies betaine was not the
only intervention, so the observed effects on lipid concen-
trations could have been due to factors other than betaine
supplementation. Furthermore, in the study with obese
individuals, weight changes might have contributed to the
changes in serum lipids [9]. The effects of betaine on lipid
metabolism in healthy humans are not well established.
Choline, the precursor of betaine, also occurs naturally in
foods, mainly as phosphatidylcholine. Daily intake of choline
is generally estimated to be 0.3–1 g [14]. Phosphatidylcholine
is an essential component of very low density lipoproteins
(VLDLs) and is therefore involved in lipid metabolism.
Animal and human studies indicate that choline deﬁciency
decreases serum cholesterol, which can be prevented by
addition of choline [15–17]. Data on the effects of choline
supplementation on blood lipids in humans are scarce.
Increases in blood lipid concentrations due to betaine or
choline supplementation might offset the potential beneﬁcial
effects of their homocysteine-lowering properties. Folic acid
is the most commonly used homocysteine-lowering agent.
The betaine remethylation and folic acid remethylation
pathways are interrelated (Figure 1), so effects of folic acid
supplementation on lipid metabolism cannot be excluded
[18].
In this study we investigated the effects of supplementation
of three homocysteine-lowering nutrients, betaine, choline
(as phosphatidylcholine), and folic acid, on blood lipid
concentrations in healthy humans. For this, we combined
data of four placebo-controlled studies in healthy humans,
performed by our group. These are the only available
randomized, controlled studies in healthy humans on this
matter that we are aware of.
Methods
Data were derived from four placebo-controlled interven-
tion studies (studies 1, 2, 3 and 4) into the effects of betaine,
phosphatidylcholine, and folic acid on homocysteine concen-
trations (Table 1). All studies are reported in accordance with
the CONSORT guidelines (Tables S1–S4).
Study 1
Study participants and design. The primary endpoint of
this study was plasma homocysteine concentrations, and
these results have been published [7]. Blood lipid measure-
ments were done post-hoc. Study 1 was conducted according
to Good Clinical Practice guidelines at TNO Quality of Life
(Zeist, the Netherlands). The local medical ethics committee
approved the protocol, and all volunteers gave their written
informed consent. Volunteers were recruited from April to
May 2000. Eligible volunteers were healthy as assessed by
routine medical screening and a general health question-
naire, had plasma total homocysteine concentrations below
25 lmol/l, had no history of cardiovascular disease, and had
not used vitamin B supplements more than once a week in
the 3 mo before entering the study. Out of the eligible
participants, the 36 participants (15 males and 21 females, age
30–50 y) with the highest plasma total homocysteine concen-
trations (range 8.9 to 21.0 lmol/l) were included in this
placebo-controlled, double-blind parallel study (Figure 2).
Participants were stratiﬁed by gender and plasma homocys-
teine concentration, and then randomly assigned to one of
three treatments for 6 wk: (a) 6 g/d of betaine (n = 12) (BUFA
Pharmaceutical Products, Uitgeest, the Netherlands), (b) 0.8
mg/d of folic acid (n = 12), or (c) placebo (n = 12). One
Figure 1. Role of Folic Acid, Choline, and Betaine in Homocysteine
Metabolism and in Phosphatidylcholine Metabolism
Phosphatidylcholine is necessary for synthesis of VLDL, which
exports lipids from the liver.
DOI: 10.1371/journal.pmed.0020135.g001
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Homocysteine Lowering and Blood Lipidsperson at the local pharmacy assigned codes to the study
treatments and provided the key in a sealed envelope to the
principal investigator at TNO. The statistician then randomly
allocated treatment codes to participant numbers. Random-
ization was done using a computerized procedure that
produced combinations based on random seed numbers.
The statistician supplied the medical investigator with sealed
envelopes with the treatment allocation per participant. The
participants and all others involved in this study were
unaware of treatment allocation. The principal investigator
performed unblinding of the treatment allocation after the
study had ended, laboratory analyses were complete, and
datasets were locked. The study supplements were dissolved
in water and ingested on two daily occasions, one half of the
daily dose after breakfast and the other half after the evening
meal. Throughout the study, participants were asked to
refrain from eating products based on animal liver and to
consume no more than two eggs per week. (Eggs and liver are
major sources of betaine and of choline, the dietary precursor
for betaine.)
Blood sampling and blood lipid analysis. Venous blood was
taken from an anticubital vein in the forearm following an
overnight fast at baseline and after 2 wk and 6 wk of
intervention. Immediately after collection, blood was mixed
well and put on ice. Within 30 min samples were centrifuged
for 10 min at 2,000 g at 4 8C. Samples were stored below  20
8C. Samples were coded to hide the identity and treatment of
participants. All samples obtained from one participant were
analysed in the same run. We measured blood lipid
concentrations in fasting EDTA plasma samples at baseline
and after 2 wk of intervention, and in fasting serum samples
collected at baseline and after 6 wk of intervention.
Concentrations of total cholesterol, high-density lipoprotein
(HDL) cholesterol, and triacylglycerol were measured with a
Hitachi (Tokyo, Japan) 911 analyzer and enzymatic assays of
Roche (Basel, Switzerland). LDL cholesterol concentrations
were calculated with the formula of Friedewald et al. [19].
Study 2
Participants and design. The primary endpoint of this
study was plasma homocysteine concentrations, and these
results have been published [8]. Blood lipid measurements
were done post-hoc. Study 2 was conducted according to
Good Clinical Practice guidelines at TNO Quality of Life
(Zeist, the Netherlands). The local medical ethics committee
Figure 2. Flow Diagram of Participant Progress through Study 1
DOI: 10.1371/journal.pmed.0020135.g002
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Homocysteine Lowering and Blood Lipidsapproved the protocol, and all volunteers gave their written
informed consent. Volunteers were recruited from Septem-
ber to October 2001. Eligible volunteers were healthy as
assessed by a general health and lifestyle questionnaire, blood
pressure measurement, and blood analyses of haematology,
homocysteine, B vitamins, liver enzymes, creatinine, glucose,
and lipids. Plasma total homocysteine concentrations were
below 25 lmol/l. Volunteers had no history of CVD, and had
not used vitamin B supplements more than once a week in
the 3 mo before entering the study. Out of the eligible
participants, the 76 participants (44 males and 32 females, age
30–50 y) with the highest plasma total homocysteine concen-
trations (range 8.4 to 22.2 lmol/l) were included in this
placebo-controlled, double-blind parallel trial (Figure 3).
Volunteers were stratiﬁed by gender, plasma homocysteine
concentration, blood pressure, and smoking (yes or no), and
then randomly assigned to one of four treatment groups for 6
wk: (a) 1.5 g/d of anhydrous betaine (BUFA) (n = 19), (b) 3 g/d
of betaine (n = 19), (c) 6 g/d of betaine (n = 19), or (d)
placebo (n = 19). One person at the local pharmacy assigned
codes to the study treatments and provided the key in a
sealed envelope to the principal investigator at TNO. The
statistician then randomly allocated treatment codes to the
participant numbers. Randomization was done using a
computerized procedure that produced combinations based
on random seed numbers. The statistician supplied the
principal investigator with sealed envelopes with the treat-
ment allocation per participant. The participants and all
others involved in this study were unaware of treatment
allocation. The statistician performed unblinding of the
treatment allocation after the study had ended, laboratory
analyses were complete, and datasets were locked. The study
supplements were dissolved in water and ingested on two
daily occasions, one half of the daily dose after breakfast and
the other half after the evening meal. Throughout the study
participants were asked not to consume liver products more
than twice a week, and not to consume more than two eggs
per week. Six grams per day of betaine is the lowest
therapeutic dose used to lower plasma homocysteine in
hyperhomocysteinemic patients with genetic defects in their
homocysteine metabolism [20]. We chose to study doses of
betaine lower than 6 g/d, e.g., 1.5 g/d and 3 g/d, because these
are within the range of intake of betaine with foods. Intake of
betaine with foods is generally estimated at 0.5–2 g/d.
Blood sampling and blood lipid analysis. Venous blood was
taken from the anticubital vein in the forearm following an
overnight fast at baseline and after 2 wk and 6 wk of
intervention. Samples were mixed and put on ice immedi-
ately after collection. Within 30 min samples were centri-
fuged for 10 min at 2,000 g at 4 8C. Samples were stored below
 18 8C. Samples were coded to hide the identity and
treatment of participants. All samples obtained from one
participant were analyzed in the same run. We measured
blood lipid concentrations in fasting EDTA plasma samples at
baseline and after 2 wk of intervention, and in fasting heparin
plasma samples collected at baseline and after 6 wk of
intervention. Concentrations of total cholesterol, HDL
cholesterol, and triacylglycerol were measured with a Hitachi
911 analyzer and enzymatic assays of Roche. LDL cholesterol
concentrations were calculated with the formula of Friede-
wald et al. [19].
Study 3
Participants and design. The primary endpoints of this
study were plasma homocysteine concentrations and vascular
function. Blood lipid measurements were planned before the
study took place, but power analysis was based on changes in
the primary endpoint vascular function, and not on changes
in blood lipids. The original study protocol of this study can
be found in Protocol S1, and the trial was registered at
clinicaltrials.gov under identiﬁer NCT00102843. The study
was conducted at the division of Human Nutrition, Wage-
ningen University (Wageningen, the Netherlands). The local
medical ethics committee approved the protocol, and all
volunteers gave their written informed consent. Volunteers
were recruited from June to September 2002. Eligible
volunteers were healthy as assessed by routine medical
screening and a general health questionnaire, had plasma
total homocysteine concentrations below 26 lmol/l, had no
history of CVD; and had not used vitamin B supplements
more than once a week in the 3 mo before entering the study.
Out of the eligible participants, the 40 participants (23 males
and 17 females, age 50–70 y) with the highest plasma total
homocysteine concentrations (range 10.2 to 21.7 lmol/l) were
included in this placebo-controlled, double-blind cross-over
trial (Figure 4). Participants were randomly assigned to one
Figure 3. Flow Diagram of Participant Progress through Study 2
DOI: 10.1371/journal.pmed.0020135.g003
Figure 4. Flow Diagram of Participant Progress through Study 3
DOI: 10.1371/journal.pmed.0020135.g004
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Homocysteine Lowering and Blood Lipidsout of six treatment orders, and they received each of the
following supplements for 6 wk, with a 6-wk wash out in
between: (a) 6 g/d of betaine (BUFA), (b) 0.8 mg/d of folic acid,
or (c) placebo. A person not further involved in the study
assigned codes to the study treatments, and randomly
allocated the selected participants to one out of six treatment
orders, according to a computer-generated randomization
list, and kept the key in a sealed envelope. The participants
and all others involved in this study were unaware of
treatment allocation. The principal investigator performed
unblinding of the treatment allocation after the study had
ended and laboratory analyses were complete. The study
supplements were dissolved in water and ingested twice per
day, one half of the daily dose after breakfast and the other
half after the evening meal. During the study participants
were not allowed to consume supplements containing B
vitamins, antioxidant vitamins (A, beta-carotene, C, and E), or
omega-3 fatty acids/ﬁsh oil supplements.
Blood sampling and laboratory analyses. Venous blood was
taken from the antecubital vein following an overnight fast
on days 41 and 43 of each treatment period. Blood was
collected in vacutainer tubes containing clot activator and a
gel to separate serum and cells. About 30 min after collection,
samples were centrifuged for 15 min at 2,000 g at 4 8C. All
serum samples were stored below 70 8C. Samples were coded
to hide the identity and treatment of participants. All samples
obtained from one participant were analyzed in the same run.
In serum samples we measured concentrations of total
cholesterol, HDL cholesterol, and triacylglycerols on a
Synchron LX 20 system (Beckman Coulter, Mijdrecht, the
Netherlands). LDL cholesterol concentrations were calcu-
lated with the formula of Friedewald et al. [19].
Study 4
Participants and design. The primary endpoint of study 4
was plasma homocysteine concentrations. Blood lipid meas-
urements were planned before the study took place, but
power analysis was based on changes in the primary endpoint
homocysteine concentrations, and not on changes in blood
lipids. The original study protocol of this study can be found
in Protocols S2–S4, and the trial was registered at clinical-
trials.gov under identiﬁer NCT00102232. This study was
conducted according to Good Clinical Practice guidelines at
TNO Quality of Life (Zeist, the Netherlands). The local
medical ethics committee approved the protocol, and all
volunteers gave their written informed consent. Volunteers
were recruited from March to May 2003. Eligible volunteers
were healthy as assessed by physical examination, a general
health and lifestyle questionnaire, blood pressure measure-
ment, routine clinical laboratory tests, and blood analyses of
homocysteine and B vitamins. Plasma homocysteine concen-
trations were below 26 lmol/l. Volunteers had no history of
CVD, and had not used vitamin B supplements, lecithin, or
supplements containing choline, choline derivatives, or
betaine more than once a week during the 1 mo before
screening. Out of the eligible men, the 26 men between 50–71
y of age with the highest plasma homocysteine concentrations
(range 11.0 to 23.1 lmol/l) were included in this placebo-
controlled, double-blind cross-over trial (Figure 5). Partic-
ipants were stratiﬁed by plasma homocysteine concentrations
at screening and by smoking habits and then randomly
assigned to one of two treatment orders; they received each
of the following supplements for 2 wk, with a 2-wk wash out in
between: (a) 34.0 g of a soybean lecithin preparation, in which
phosphatidylcholine is the only phospholipid (PhosChol
Nutrasal, Oxford, Connecticut, United States) and (b) placebo
oil, which consisted of 25.5 g of a mixture of edible oils that
mimicked the fatty acid composition of the phosphatidylcho-
line supplement (provided by Unilever Research Laboratory,
Vlaardingen, the Netherlands) (Table 2). A person not further
involved in the study assigned codes to the study treatments
and provided the key in a sealed envelope to the principal
investigator at TNO. The statistician randomly allocated the
Figure 5. Flow Diagram of Participant Progress through Study 4
DOI: 10.1371/journal.pmed.0020135.g005
Table 2. Composition of Treatment Supplements in Study 4
Component Phosphatidylcholine
Supplement
a
Placebo
b
Dose ingested by the participants (g/d) 34 25.5
Protein (g/d) 2.7 Not present
Carbohydrate (g/d) 2.4 Not present
Fat (g/d) 25.5 25.5
Choline (g/d)
c 2.6 Not detectable
Amount of fatty acids (g/d)
d 22.0 21.8
Main fatty acids (g/d)
C8 (caprylic acid) 3.0 2.0
C10 (capric acid) 1.4 1.7
C16 (palmitic acid) 2.1 1.0
C18 (stearic acid) 0.6 0.6
C18:1n-9 (oleic acid) 1.8 4.0
C18:2n-6 (linoleic acid) 11.7 10.4
C18:3n-3 (a-linolenic acid) 1.0 1.4
a PhosChol consisted of 80% of a soybean lecithin extract (‘‘Phosal 75A’’), 18% medium-chain triglyceride mix, and
traces of D alpha-tocopherol and paraben blend. The soybean lecithin extract consisted of 8% moisture, 3% ash,
10% protein, 71% fat (including phosphatidylcholine), 9% carbohydrates, and traces of vitamins and minerals. Folic
acid content of the soybean lecithin extract was 195 lg/kg, which is approximately 5 lg per 34 g of
phosphatidylcholine oil (calculated from data provided by the manufacturer). This amount is negligible relative to
daily intake of folic acid (100–200 lg/d).
b Placebo consisted of a mixture of linola (low-linolenic and high-linoleic linseed) oil (70%), rapeseed oil (21%), and
medium-chain triglycerides mix (9%).
c The choline content of PhosChol was measured in two different labs. The lab of S. H. Zeisel [21] measured choline
as phosphatidylcholine in two samples of PhosChol. Concentrations of phosphatidylcholine in the two samples were
800 and 801 lmol of phosphatidylcholine per gram of sample: this is approximately 20.6 g of phosphatidylcholine
(molecular weight 758), or 2.8 g of choline in 34 g of PhosChol. Total choline content was also measured in four
samples of PhosChol at TNO (see Methods). Mean choline content was 74.8 mg/g: this is 2.5 g of choline in 34 g of
PhosChol. The mean choline content from all six samples analyzed was 2.6 g/d.
d Fatty acids were measured by gas chromatography of fatty acid methyl esters [50].Trinonadecanoin (C19:0) was
used as a reference compound to calculate the amounts of individual fatty acids.
DOI: 10.1371/journal.pmed.0020135.t002
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Homocysteine Lowering and Blood Lipidsselected participants to one of the two treatment orders.
Randomization was done using a computerized procedure
that produced combinations based on random seed numbers.
The statistician supplied the principal investigator with
sealed envelopes with the treatment allocation per partic-
ipant. The participants and all others involved in this study
were unaware of treatment allocation. The statistician
performed unblinding of the treatment allocation after the
study had ended, laboratory analyses were complete, and
datasets were locked. Phosphatidylcholine and placebo
supplements were matched for fat content and fatty acid
composition (Table 2). The amount of choline in 34 g of the
phosphatidylcholine supplement was 2.6 g, as measured by
Koc et al. [21] and by TNO. The daily dose of 2.6 g of choline
is well below the current tolerable upper intake level of 3.5 g
of choline per day for adults [22]. Participants ingested half of
the daily supplement dose two times per day (i.e., at breakfast
and at dinner). The individual portions of half the daily dose
of the supplements were mixed with 200 ml of custard.
Participants returned 99.5% of the bowls empty, which
indicated good compliance. From 2 wk before the start of
the study until the end of the study participants were not
allowed to consume food products rich in lecithin or betaine.
Blood sampling and laboratory analyses. Venous blood was
taken from the antecubital vein following an overnight fast
on days 13 and 15 of each treatment period. Blood was
collected in vacutainer tubes containing clot activator and a
gel to separate serum and cells. About 30 min after collection,
samples were centrifuged for 15 min at 2,000 g at 4 8C. All
serum samples were stored below 70 8C. Samples were coded
to hide the identity and treatment of participants. All samples
obtained from one participant were analyzed in the same run.
In serum samples we measured concentrations of total
cholesterol, HDL cholesterol, and triacylglycerols with a
Hitachi 911 analyzer and enzymatic assays of Roche. LDL
cholesterol concentrations were calculated with the formula
of Friedewald et al. [19]. For the measurement of choline at
TNO, choline was liberated from the sample by boiling the
sample for 4 h with nitric acid (17 v/v%). After ﬁltration of
the sample, the pH of the extract was raised to 9.0 with
sodium hydroxide solution. To an aliquot part of the extract
a solution of ammonium reineckate in methanol was added,
which formed the insoluble choline reineckate. The precip-
itate was ﬁltered off and dissolved in acetone. The color of
the acetone solution was determined with a spectrophotom-
eter at a wavelength of 530 nm.
Statistics
The sample size of each study was based on power analysis
for the primary outcome measure. To exclude effects of the
matrix in which lipids were measured [23], all changes in lipid
concentrations within persons or studies were based on
measurements within the same matrix. So choice of matrix
could not have been responsible for differences in results
between the studies. First we calculated the mean change in
lipid concentrations relative to placebo after supplementa-
tion with the treatments for each study. Means were
compared with the General Linear Models procedure in
SAS (ANOVA; SAS version 6.12, SAS Institute, Cary, North
Carolina, United States). For the parallel studies 1 and 2,
Dunnett’s two-tailed t-test was used to test whether any of the
treatments signiﬁcantly differed from placebo. For the cross-
over studies 3 and 4, a paired Student’s t-test was used to test
whether any of the treatments signiﬁcantly differed from
placebo. Then we combined the lipid data of the studies with
betaine or folic acid supplementation. For this we calculated
a combined effect of all four studies, which was a weighted
mean and 95% conﬁdence intervals of the change in lipid
concentrations relative to placebo after betaine supplemen-
tation (studies 1, 2, and 3), and after folic acid supplementa-
tion (studies 1 and 3) according to the method used by Curtin
et al. [24] (Tables 3 and 4). We tested whether the weighted
mean changes differed from zero with a t-test. For all tests
mean differences were considered statistically signiﬁcant at p
, 0.05.
Results
All participants completed the study, except for one male
participant who withdrew from study 3 due to emigration. No
serious adverse events were reported in any of the studies.
Non-serious adverse events are shown in Table S5.
Supplementation of 6 g/d of betaine for 6 wk increased
total cholesterol concentrations by 0.42 mmol/l (8%) relative
to placebo (see Table 3). This increase was almost completely
accounted for by an increase in LDL cholesterol concen-
trations of 0.36 mmol/l (11%). Betaine increased triacylgly-
cerol concentrations by 0.14 mmol/l (13%). HDL cholesterol
concentrations did not change, but the ratio of total to HDL
cholesterol concentration increased by 0.23 (6%). The
increases in LDL cholesterol concentrations in the groups
that ingested 1.5 g/d of betaine and 3 g/d of betaine for 6 wk
were higher than in the placebo group, but these changes did
not reach statistical signiﬁcance (Figure 6). The effects of
betaine supplementation on LDL cholesterol concentrations
were already evident after 2 wk of supplementation in studies
1 and 2.
Supplementation of 0.8 mg/d of folic acid for 6 wk did not
affect lipid concentrations in healthy volunteers (see Table 4).
Supplementation with 2.6 g/d of choline (provided as
phosphatidylcholine) for 2 wk increased serum triacylglycer-
ols by 0.14 mmol/l (8%), but did not affect cholesterol
concentrations (Table 5).
Discussion
We found that supplementation of 6 g/d of betaine for 6 wk
consistently increased total cholesterol concentrations,
mainly LDL cholesterol, and triacylglycerol concentrations.
Phosphatidylcholine supplementation for 2 wk increased only
serum triacylglycerol concentrations. Folic acid supplemen-
tation did not affect lipid concentrations.
The three studies on betaine supplementation were not
originally designed to investigate changes in blood lipids.
Therefore, we did not performp o w e rc a l c u l a t i o n sf o r
changes in blood lipids for each study beforehand. We
combined the lipid data of the three studies to have a better
estimate of the effects of betaine on blood lipids, and thereby
increase the statistical power afterwards. Similarly we did not
do power calculations for effects of folic acid on blood lipids.
The increase in LDL cholesterol concentrations with betaine
supplementation that we found in healthy humans is in
accordance with results from previous studies in renal
patients [13] and obese individuals who were on a weight-
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Homocysteine Lowering and Blood Lipidsloss diet [9]. Doses of betaine lower than 6 g/d also raised LDL
cholesterol, although this did not reach statistical signiﬁcance
(Figure 6). Our study was not designed to investigate the
dose–response relationship between betaine doses and
changes in LDL cholesterol. Establishing the dose–response
relationship between betaine and LDL cholesterol might
require more than three betaine dose groups. Furthermore,
betaine supplementation affected blood lipids already after 2
wk of intervention (Figure 6). The increase in triacylglycerol
concentrations with betaine supplementation is well in line
with the results of Schwab et al. in obese individuals [9]. In the
obese individuals betaine supplementation increased triacyl-
glycerol concentrations by approximately 12%, although this
increase did not reach statistical signiﬁcance.
Our observations should be of speciﬁc concern for clinical
practice as well as for the general population. Patients with
inborn errors in the enzymes involved in homocysteine
metabolism and who are not or only partially responsive to
pyridoxine are generally prescribed betaine in doses of 6 g/d
or higher in order to lower their plasma homocysteine [25].
Our data imply that betaine treatment in these patients may
have adverse effects on lipid concentrations. No one has
systematically reported changes in serum cholesterol concen-
trations in hyperhomocysteinemic patients who are on
betaine treatment, although this may be warranted. Clearly
in these patients, the beneﬁt of the substantial homocysteine-
lowering effect of betaine outweighs the effect of any modest
lipid-related changes. Furthermore, our data imply that
among the general population intake of extra betaine, e.g.,
from supplements or through increased intake of betaine-
rich foods, may not bring the expected beneﬁts for CVD
prevention predicted from the homocysteine-lowering effect
of betaine.
Phosphatidylcholine supplementation increased serum
Table 5. Concentrations of Serum Lipids (mmol/l) and the Ratio of Total to HDL Cholesterol in Fasting State after 26 Healthy Men Had
Ingested Phosphatidylcholine Providing ~2.6 g/d of Choline or Placebo for 2 Wk
Blood lipid Placebo
(Mean [SD])
Phosphatidylcholine
Supplement (Mean [SD])
Change Relative to Placebo
(Mean [95% CI])
Total cholesterol 5.7 (0.8) 5.7 (0.9) 0.1 ( 0.1; 0.3)
HDL cholesterol 1.3 (0.3) 1.3 (0.3)  0.0 ( 0.1; 0.0)
LDL cholesterol
a 3.6 (0.8) 3.6 (0.8)  0.0 ( 0.2; 0.2)
Triacylglycerols 1.77 (1.15) 2.00 (1.27) 0.14 (0.06; 0.21)
b,c
Ratio total/HDL 4.6 (1.4) 4.8 (1.4) 0.2 ( 0.0; 0.3)
a Data from two participants were missing because serum triacylglycerol concentrations were .4.5 mmol/l and under these circumstances calculation of LDL concentrations with the Friedewald formula [19] gives unreliable results.
b Results were based on log-transformed values, because values were not normally distributed.
c Significantly different from placebo, p , 0.05.
DOI: 10.1371/journal.pmed.0020135.t005
Table 4. Mean Changes in Blood Lipid Concentrations and the Ratio of Total to HDL Cholesterol in Fasting State in Studies 1 and 3, and
the Combined Effect of Supplementation with 0.8 mg/d of Folic Acid
Blood Lipid Study Treatment Group Lipid Concentrations at
Baseline (Study 1) or
after Placebo
Supplementation
for 6 Wk (Study 3)
(mmol/l) (Mean [SD])
Lipid Concentrations
after Folic Acid
Supplementation
for 6 Wk (mmol/l)
(Mean [SD])
Change Relative
to Placebo (mmol/l)
(Mean [95% CI])
Total cholesterol Study 1 Folic acid group 5.06 (0.69) 5.14 (0.73) 0.36 ( 0.11; 0.83)
Study 3 5.67 (0.64) 5.53 (0.71)  0.14 ( 0.28;  0.01)
a
Combined effect of folic acid  0.10 ( 0.22; 0.03)
HDL cholesterol Study 1 Folic acid group 1.46 (0.39) 1.46 (0.36) 0.02 ( 0.09; 0.14)
Study 3 1.34 (0.40) 1.32 (0.41)  0.02 ( 0.06; 0.02)
Combined effect of folic acid  0.02 ( 0.05; 0.02)
LDL cholesterol Study 1 Folic acid group 3.12 (0.55) 3.19 (0.71) 0.38 ( 0.04; 0.81)
Study 3 3.95 (0.54) 3.83 (0.60)  0.11 ( 0.23;  0.00)
a
Combined effect of folic acid  0.07 ( 0.18; 0.03)
Triacylglycerols Study 1 Folic acid group 1.05 (0.27) 1.08 (0.26)  0.10 ( 0.47; 0.28)
Study 3 1.06 (0.40) 1.01 (0.39)  0.05 ( 0.13; 0.03)
Combined effect of folic acid  0.05 ( 0.13; 0.02)
Ratio total/HDL cholesterol Study 1 Folic acid group 3.60 (0.66) 3.67 (0.74) 0.16 ( 0.20; 0.52)
Study 3 4.50 (1.03) 4.48 (1.08)  0.02 ( 0.15; 0.10)
Combined effect of folic acid 0.00 ( 0.11; 0.12)
Study 1 is a parallel study with 12 participants per group; study 3 is a cross-over study with 39 participants. Lipid concentrations of the placebo group in study 1 are presented in Table 3.
a Significantly different from placebo, p , 0.05
DOI: 10.1371/journal.pmed.0020135.t004
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Homocysteine Lowering and Blood Lipidstriacylglycerols, but did not affect serum cholesterol concen-
trations. We supplemented phosphatidylcholine for only 2
wk, and it is possible that this was too short to induce changes
in serum cholesterol, although betaine supplementation did
increase blood cholesterol concentrations within 2 wk. We
carefully matched the fat content and fatty acid composition
of the control and the phosphatidylcholine supplements.
Previous studies that also attempted to control for the fatty
acid component of lecithin (the trivial name for phosphati-
dylcholine) [26–30], or that tested choline bitartrate [31],
suggest that there is little or no effect of the choline moiety of
lecithin on blood lipids, provided that the fatty acids in
lecithin are balanced in the placebo treatment. Only two of
the studies that investigated phosphatidylcholine included a
concurrent control group [27,30]. In the randomized cross-
over study of Childs et al. [27] triacylglycerol concentrations
in 12 normolipidemic individuals were 0.01 mmol/l lower
after they had consumed lecithin for 3 wk than after they had
consumed placebo. Oosthuizen et al. [30] found in a parallel
study with seven hyperlipidemic men per group that the
median triacylglycerol concentration decreased by 0.19
mmol/l in the lecithin group relative to the placebo group
after 2 wk of intervention. After 4 wk of intervention this
difference had disappeared. The increase in triacylglycerol
concentrations with phosphatidylcholine treatment in our
study could be a chance ﬁnding. However, our study was
larger than previous studies, we used a cross-over design with
a wash out period, and participants received supplements in
random order. Moreover, the dose of phosphatidylcholine we
used was higher than in the previous studies. Therefore, our
study leaves open a real possibility that the choline moiety of
phosphatidylcholine in high doses raises serum triacylglycerol
concentrations.
We propose that the mechanism by which betaine and
phosphatidylcholine supplementation increase blood lipid
concentrations involves increased export of lipids from the
liver into the circulation. Lipids are exported from the liver
through VLDL particles, which consist of a triglyceride core
packaged in an amphipatic shell of phospholipids, mostly
phosphatidylcholine, and apolipoprotein B-100. More VLDL
will increase transport of lipids from the liver into the blood,
and concentrations of lipids in the liver decrease accordingly
[11]. Betaine and phosphatidylcholine supplementation could
increase VLDL synthesis via increased availability of phos-
phatidylcholine, an essential component of VLDL (see Figure
1) [32]. Furthermore, betaine might increase phosphatidyl-
choline synthesis owing to increased availability of S-
adenosylmethionine via increased remethylation of homo-
cysteine into methionine, because S-adenosylmethionine is
the methyl donor for the formation of phosphatidylcholine
out of phosphatidylethanolamine [33]. In addition, betaine
supplementation could promote phosphatidylcholine syn-
thesis through increasing the activity of the enzyme betaine–
homocysteine methyltransferase [34]. Betaine–homocysteine
methyltransferase catalyzes the transfer of a methyl group
from betaine to homocysteine, but it also catalyzes the ﬁrst
step in the three-enzyme pathway that promotes methylation
of phosphatidylethanolamine into phosphatidylcholine
[35,36].
We speculate that betaine and phosphatidylcholine sup-
plementation increase lipid concentrations in blood because
of increased synthesis and availability of phosphatidylcholine,
which promotes VLDL secretion from the liver into plasma,
resulting in higher lipid concentrations in blood [32,37].
Our data indicate that folic acid supplementation does not
affect serum lipid concentrations, which is in agreement with
other studies [38–41].
The consequences of betaine or phosphatidylcholine
supplementation for risk of CVD are difﬁcult to predict. In
healthy participants, betaine supplementation lowers plasma
homocysteine after methionine loading by 20%–40%. Be-
taine as well as phosphatidylcholine supplementation lower
fasting plasma homocysteine by 12%–20% (Table 6) [7,8].
This is estimated to lower CVD risk by 10%–15% [1,42].
However, it is not yet ﬁrmly established that homocysteine
lowering indeed lowers risk of CVD, although evidence for a
causal relationship is accumulating [1–3,43]. We now ﬁnd that
betaine not only decreases homocysteine, but also increases
LDL cholesterol by approximately 10% and the total/HDL
cholesterol ratio by approximately 6%. This is estimated to
increase CVD risk by approximately 10% [44–46]. Betaine (6
Table 6. Percentage Change in Fasting Concentrations of
Plasma Homocysteine after Participants Had Ingested Betaine
and Folic Acid for 6 Wk
Supplement Dose Percentage Change
in Plasma
Homocysteine
Concentrations
Relative to Placebo
Betaine
a Study 1: 6 g/d of betaine 15%
Study 2: 6 g/d of betaine, 3 g/d
of betaine, or 1.5 g/d of betaine
20%, 15%, and 12%,
respectively
Study 3: 6 g/d of betaine 12%
Folic acid Study 1: 0.8 mg/d of folic acid 21%
Study 3: 0.8 mg/d of folic acid 20%
Sources: [7,8].
a The magnitude of the effect of 2.6 g/d of phosphatidylcholine supplementation on fasting plasma homocysteine is
comparable to the effect of betaine on plasma homocysteine in humans [51].
DOI: 10.1371/journal.pmed.0020135.t006
Figure 6. Mean Change Relative to Placebo in LDL Cholesterol
Concentrations
Compared are the values after participants had ingested 1.5 g/d of
betaine (study 2, n=19), 3 g/d of betaine (study 2, n=18), or 6 g/d of
betaine (studies 1 and 2 combined, n=31) after 2 wk (þ95%
conﬁdence interval) and 6 wk (–95% conﬁdence interval). In the
group that ingested 3 g/d of betaine one participant missed the blood
collection before treatment.
DOI: 10.1371/journal.pmed.0020135.g006
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d of choline) supplementation increase triacylglycerol con-
centrations by up to 13%, which is estimated to increase risk
of CVD by approximately 6%, after adjustment for other risk
factors [47–49]. This implies that betaine supplementation is
expected to increase risk of CVD if homocysteine is not a
cause of CVD, or does not affect risk if homocysteine is
causally involved. Whether phosphatidylcholine affects CVD
risk remains uncertain so far.
Observational studies could help in assessing the overall
effect of phosphatidylcholine and betaine consumption on
CVD risk. Recently, data on betaine and choline contents in
foods became available [10], so it should now be feasible to
assess the relationship between betaine and phosphatidylcho-
line intake and risk of CVD. In summary, the adverse effects
of betaine on blood lipids make it less suitable as a
homocysteine-lowering agent in healthy humans. Phosphati-
dylcholine may be more suitable because it only slightly
increases serum triacylglycerol concentrations and does not
affect LDL cholesterol. Folic acid has no adverse side effects
on blood lipids, and therefore folic acid supplementation
should remain the preferred homocysteine-lowering treat-
ment in healthy humans.
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Patient Summary
Background Homocysteine is an amino acid in the blood (amino acids
are the building blocks of proteins). Too much homocysteine in the
blood is related to a higher risk of stroke and heart disease. Mildly
elevated levels (which are quite common) might promote atherosclerosis
(furring up of the arteries), but this link has not been proven yet. Studies
are currently under way to test whether reducing homocysteine levels in
people who have mildly elevated levels could prevent heart disease or
stroke. Again, the results are not yet known.
Why Was This Study Done? In people who have dramatically elevated
levels of homocysteine, different food supplements have been shown to
bring down homocysteine concentrations and to reduce the risk of heart
disease and strokes. These supplements include folic acid, vitamin B12,
vitamin B6, betaine, and phosphatidylcholine. This study looked at the
effects of betaine, folic acid, and phosphatidylcholine on blood lipids in
healthy people. The researchers wanted to study blood lipids, especially
‘‘bad’’ cholesterol (LDL cholesterol), because they are known to influence
the risk of heart disease.
What Did the Researchers Do? They analyzed data from four different
studies that looked at the ability of the three substances to lower
homocysteine levels. They analyzed the blood samples (which had
previously been used to measure homocysteine) for lipid levels.
What Did They Find? They found that betaine increased the level of
‘‘bad’’ cholesterol. Folic acid did not affect lipid levels. The data for
phosphatidylcholine were not conclusive.
What Does This Mean? This suggests that the beneficial effects of
betaine (which lowers homocysteine) might be undone at least in part
by its negative effects on blood lipids. Based on these results, folic acid
would be a better choice for people who want to lower their
homocysteine levels, since folic acid doesn’t cause a rise in ‘‘bad’’
cholesterol.
More Information Online
More information on the link between homocysteine and heart disease
can be found at the following Web sites. Web site of the American Heart
Association (search for ‘‘homocysteine’’ or ‘‘cholesterol’’): http://www.
americanheart.org/presenter.jhtml?identifier = 1200000
Web site of the Australian Heart Association (search for ‘‘homocysteine,’’
‘‘cholesterol,’’ and ‘‘cardiovascular risk’’): http://www.heartfoundation.
com.au/
Web site of the British Heart Foundation (search for ‘‘homocysteine,’’
‘‘cholesterol,’’ and ‘‘cardiovascular risk’’): http://www.bhf.org.uk/
WebMD Web pages on homocysteine, cholesterol, and heart disease (or
search http://webmd.com for ‘‘homocysteine’’ or ‘‘cholesterol’’): http://
my.webmd.com/content/pages/9/1675_57859; http://my.webmd.com/
content/pages/9/1675_57815
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